Abbott Laboratories (ABT), headquartered in Lake County, Illinois, is preparing to release its Q1 2026 earnings report. The healthcare giant, which has a market capitalization of $181.2 billion, operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Analysts anticipate the company's earnings per share (EPS) to be $1.15 on a diluted basis for the upcoming quarter, representing a 5.5% increase from the year-ago quarter of $1.09. Historically, Abbott has either met or exceeded Wall Street's EPS estimates in each of its last four quarters.
Looking further ahead, fiscal 2026 analysts project an EPS of $5.68, which would be a 10.3% rise from the $5.15 recorded in fiscal 2025. Forecasts extend into fiscal 2027 with an expected EPS increase of roughly 9.9% year over year to reach $6.24. The stock has shown recent volatility, having fallen nearly 10% on January 22 following its mixed Q4 2025 earnings report where revenue of $11.5 billion missed estimates, although adjusted EPS of $1.50 beat the Street's expectations. Over the past 52 weeks, ABT stock has declined by 16.9%, significantly underperforming the S&P 500 Index's 13.7% gain and trailing the State Street Healthcare Select Sector SPDR ETF's performance during the same period.
Investor sentiment remains strongly positive toward Abbott, with the stock holding a "Strong Buy" rating overall among the 28 analysts covering the company. The consensus recommendation breaks down as 20 "Strong Buys," two "Moderate Buys," and six "Holds." Based on this analyst coverage, ABT's average price target stands at $134.21, indicating a potential upside of 29% from current levels. This bullish outlook contrasts with the recent price underperformance, suggesting that analysts anticipate significant future growth in earnings to align with long-term projections despite the stock's recent dip relative to the broader market and sector peers.
🏭 Abbott operates globally with an $181.2B market cap across four segments.
📈 Projected EPS grows to $6.24 in 2027, beating estimates for four quarters.
📉 Shares dropped 16.9% recently despite a "Strong Buy" rating from 28 analysts.
🏭 Abbott Laboratories, headquartered in Lake County, Illinois, operates globally with a $181.2 billion market cap across four main segments.
💰 Analysts project Q1 2026 earnings per share (EPS) of $1.15, representing a 5.5% increase from the previous year's quarter.
📈 The company has consistently met or exceeded Wall Street EPS estimates for the last four consecutive quarters.
📅 For fiscal 2026, projected EPS is $5.68 (up 10.3%), with a further rise to $6.24 expected for fiscal 2027.
📉 ABT stock has declined 16.9% over the past 52 weeks, significantly underperforming the S&P 500's 13.7% gain.
📊 On January 22, shares dropped nearly 10% after Q4 2025 revenue of $11.5 billion missed estimates despite EPS beating expectations.
🏆 The stock holds an overall "Strong Buy" rating among 28 analysts covering the company.
💡 Of the 28 analysts, 20 recommend a "Strong Buy," two suggest a "Moderate Buy," and six advise a "Hold."
🎯 The average analyst price target is set at $134.21, suggesting approximately 29% upside from current levels.
Bullish Signals
Analysts expect Abbott's Q1 2026 EPS to reach $1.15, representing a 5.5% increase from the year-ago quarter of $1.09.
The company has successfully surpassed or met Wall Street's EPS estimates in each of its last four quarters, demonstrating consistent performance.
Full-year fiscal 2026 EPS is projected to hit $5.68, marking a 10.3% rise from the previous year's $5.15.
Analysts anticipate further growth with an expected 9.9% year-over-year increase in EPS to reach $6.24 in fiscal 2027.
Abbott currently holds a 'Strong Buy' rating overall, with 20 out of 28 analysts recommending the stock as 'Strong Buy'.
The average analyst price target is set at $134.21, indicating a significant 29% upside potential from current levels.
Despite recent revenue misses, the company managed to beat adjusted EPS expectations by delivering $1.50 per share in Q4 2025.
Risk Factors
ABT stock has declined 16.9% over the past 52 weeks, significantly underperforming the S&P 500 Index's 13.7% rise during the same period.
Q4 2025 revenue came in at $11.5 billion, falling short of Wall Street estimates despite adjusted EPS beating expectations.
On Jan. 22, ABT stock fell nearly 10% immediately following the release of mixed Q4 2025 earnings.
Six analysts advise a 'Hold' on the stock compared to a more bullish outlook, indicating some uncertainty about future performance.
The company's current market cap is $181.2 billion, which may limit agility if it faces significant revenue headwinds or regulatory scrutiny.
Analysts have recently released new ratings on three healthcare companies: Abbott Laboratories, Pfizer, and Wave Life Sciences. Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT) with a price target of $122.00. As of the report date, Abbott's shares closed last Monday at $104.85, near its 52-week low of $99.71. Biegelsen, who covers Abbott along with other healthcare stocks like Anteris Technologies Global Corp., holds a 2-star analyst rating on TipRanks.com with an average return of 0.4% and a 47.1% success rate. The general market consensus suggests a Strong Buy for Abbott Laboratories with an average price target of $137.14, implying 28.1% upside from current levels. Additionally, TipRanks upgraded the stock to Buy with a $124.00 price target in a report issued on March 10.
For Pfizer (PFE), Steve Scala from TD Cowen maintained a Hold rating with a price target of $30.00, while Pfizer shares closed last Monday at $26.77. Scala is rated as a 5-star analyst by TipRanks.com with an average return of 10.6% and a 63.6% success rate; he also covers peers such as Merck & Company, GlaxoSmithKline, and Eli Lilly & Co. The broader Street consensus for Pfizer is a Moderate Buy with a price target consensus of $29.07, representing 7.5% upside. On March 10, UBS maintained a Hold rating on the stock with a lower $25.00 price target.
In contrast, Wedbush analyst Yun Zhong maintained a Buy rating on Wave Life Sciences (WVE) today and set a price target of $35.00. WVE shares closed last Monday at $11.62. Zhong is ranked 0 out of 5 stars by TipRanks.com with an average return of -7.0% and a 40.1% success rate, and he also covers Sagimet Biosciences, Inc., CAMP4 Therapeutics Corporation, and MoonLake Immunotherapeutics. The overall market consensus for Wave Life Sciences is a Strong Buy with an average price target of $34.40, indicating significant potential upside of 184.1% from current levels. This contrasts with a March 10 report from Canaccord Genuity which maintained a Buy rating on the stock with a higher $52.00 price target. The article notes that this content is syndicated and has not been reviewed or endorsed by the publication, and may include compensation disclosures.
Wells Fargo reaffirms a Strong Buy on Abbott with $122 price target near 52-week low.
Pfizer holds Moderate Buy consensus implying 7.5% upside from current trading levels.
Wave Life Sciences commands Strong Buy status with massive 184% potential upside to $35 target.
- 🔬 Analysts from Wells Fargo, TD Cowen, and Wedbush provided fresh insights on healthcare stocks Abbott Laboratories (ABT), Pfizer (PFE), and Wave Life Sciences (WVE).
- 🛑 Larry Biegelsen of Wells Fargo reaffirmed a Buy rating for Abbott Laboratories with a price target of $122.00, noting the stock was trading near its 52-week low.
- 📈 The general analyst consensus for Abbott remains Strong Buy with an average price target of $137.14, suggesting approximately 28% upside from current levels.
- 👔 Steve Scala of TD Cowen maintained a Hold rating on Pfizer with a price target of $30.00 while the stock closed at $26.77 last Monday.
- 🧬 Pfizer holds a Moderate Buy consensus with a price target of $29.07, implying 7.5% upside based on recent analyst reports from UBS and others.
- 🚀 Wedbush analyst Yun Zhong issued a Buy rating for Wave Life Sciences today with a price target of $35.00 despite the stock closing at $11.62.
- 💡 The broader Street consensus for Wave Life Sciences is Strong Buy, averaging a price target of $34.40 which represents a massive 184% upside from current prices.
- 🤝 Abbott Laboratories finalized its acquisition of Exact Sciences to expand its cancer diagnostics portfolio earlier this week.
- ⚠️ This article includes third-party press releases and syndicated content that has not been reviewed or endorsed by The Globe and Mail.
Bullish Signals
Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT) with a price target of $122.00, indicating analyst confidence in the company's value.
The broader analyst consensus suggests a Strong Buy rating for Abbott Laboratories with an average price target of $137.14, implying a significant 28.1% upside potential from current levels.
Abbott recently finalized its acquisition of Exact Sciences to expand its cancer diagnostics portfolio, closing the deal on March 23 as planned.
Analysts also offer a Strong Buy consensus for Wave Life Sciences (WVE) with a $34.40 average price target, representing a massive 184.1% upside from recent trading levels.
Canaccord Genuity maintained a Buy rating on Wave Life Sciences with a high price target of $52.00, reinforcing the strong positive sentiment among Wall Street professionals.
Risk Factors
Abbott Laboratories shares are trading close to their 52-week low of $99.71, indicating significant near-term weakness despite buy ratings.
The recent acquisition of Exact Sciences is set to close on March 23, which may introduce integration risks and uncertainty into Abbott's operations in the coming months.
Analyst Steve Scala from TD Cowen has assigned a Hold rating to Pfizer, suggesting cautious sentiment regarding the stock's near-term prospects.
UBS also maintained a Hold rating on Pfizer with a price target of $25.00, which is below the current trading level, indicating potential downside risk.
Wedbush analyst Yun Zhong, who maintains a Buy rating on Wave Life Sciences, has a negative track record with a -7.0% average return and 40.1% success rate.
Analysts have issued new ratings and price targets for key healthcare companies, with significant attention focused on Abbott Laboratories (ABT), Pfizer (PFE), and Wave Life Sciences (WVE). In a report released today, Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories, setting a price target of $122.00, while the stock closed last Monday at $104.85, near its 52-week low of $99.71. The broader Street consensus for Abbott is a Strong Buy with an average price target of $137.14, implying approximately 28.1% upside from current levels, following a previous upgrade to Buy by TipRanks and Google with a $124.00 target on March 10.
Conversely, analyst sentiment for Pfizer remains mixed. TD Cowen analyst Steve Scala issued a Hold rating on Pfizer today with a price target of $30.00, based on shares that closed last Monday at $26.77. Scala, a 5-star analyst according to TipRanks, covers other major pharmaceutical names including Merck and Eli Lilly. Overall, the consensus for Pfizer is Moderate Buy with a price target of $29.07, representing 7.5% upside, though UBS maintained a Hold rating with a lower $25.00 target in their March 10 report.
For Wave Life Sciences (WVE), Wedbush analyst Yun Zhong provided a Buy rating today with a price target of $35.00 against a Monday closing price of $11.62. Despite Zhong's lower individual star rating and negative historical return profile, the general Street consensus for Wave Life Sciences is Strong Buy, suggesting significant potential with a $34.40 average price target representing 184.1% upside from current levels. This optimism was reinforced by Canaccord Genuity, which maintained a Buy rating with a high $52.00 target in their March 10 report. Abbott Laboratories is also noted for finalizing its acquisition of Exact Sciences, expanding its cancer diagnostics portfolio, with the deal expected to close around March 23.
🔬 Wells Fargo maintains a Buy on Abbott with a $122 target despite near-52-week lows.
💰 Pfizer receives a Hold from TD Cowen though consensus suggests modest 7.5% upside potential.
🌊 Wedbush upgrades Wave Life Sciences to Buy with massive 184.1% implied upside opportunity.
🚀 Market sentiment varies significantly between the three major healthcare stocks covered today.
⚕ Abbott proceeds with Exact Sciences acquisition to expand its cancer diagnostics portfolio.
🔬 Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT) with a price target of $122.00.
💰 The report notes ABT shares closed near its 52-week low of $99.71, below the latest analyst price target.
📊 Street consensus for Abbott is Strong Buy with a $137.14 average price target implying 28.1% upside.
⚕️ TD Cowen's Steve Scala issued a Hold rating on Pfizer (PFE) with a price target of $30.00 per share.
📈 Pfizer maintains a Moderate Buy consensus with a $29.07 average price target suggesting 7.5% upside from current levels.
🌊 Wedbush analyst Yun Zhong upgraded Wave Life Sciences (WVE) to a Buy rating with a $35.00 price target today.
🚀 Market consensus for Wave Life Sciences is Strong Buy with an average price target of $34.40 representing 184.1% upside.
⚠️ Analyst performance metrics show varying success rates and star ratings across the three healthcare companies covered.
🩺 Abbott is also finalizing its acquisition of Exact Sciences to expand its cancer diagnostics portfolio.
Bullish Signals
Wells Fargo gives Abbott (ABT) a Buy rating with a $122.00 target.
Street consensus rates Abbott (ABT) Strong Buy at a $137.14 average target.
Abbott completes Exact Sciences acquisition to expand cancer diagnostics capabilities.
Analysts maintain a Buy rating on Wave Life Sciences (WVE) at $34.40.
Canaccord Genuity rates Wave Life Sciences (WVE) as Buy with a $52.00 target.
Risk Factors
Analyst Larry Biegelsen: 47.1% success rate; weak Buy credibility for Abbott.
Abbott shares trading near 52-week low of $99.71 amid weak sentiment.
TD Cowen maintains Hold on Pfizer with limited growth at $30.00.
UBS maintains Hold on Pfizer; lower $25.00 target reflects caution.
Abbott acquisition strains capital before Exact Sciences closes March 23.
Bullish Signals
Wells Fargo analyst Larry Biegelsen maintains a Buy rating on Abbott Laboratories (ABT) with a price target of $122.00, implying upside from current levels near $104.85.
The Street consensus indicates a Strong Buy rating for Abbott Laboratories with an average price target of $137.14, representing a significant 28.1% upside potential.
Abbott has just completed its acquisition of Exact Sciences, which will expand its cancer diagnostics capabilities.
Analysts maintain a Buy rating on Wave Life Sciences (WVE) with an average price target of $34.40, suggesting an impressive 184.1% upside from current market levels.
Canaccord Genuity maintains a Buy rating on Wave Life Sciences with an aggressive $52.00 price target, further validating positive analyst sentiment.
Risk Factors
Analyst Larry Biegelsen from Wells Fargo has a 2-star rating with only a 47.1% success rate, casting doubt on the credibility of his Buy rating for Abbott Laboratories despite the positive outlook.
Abbott's shares are trading near its 52-week low of $99.71 after closing at $104.85, indicating weak recent price performance and potential investor sentiment issues.
TD Cowen analyst Steve Scala maintains a Hold rating on Pfizer with a $30.00 price target, suggesting limited growth potential or concerns about the company's current trajectory.
UBS has also maintained a Hold rating on Pfizer with a lower $25.00 price target, reflecting divergent and cautious analyst opinions that could pressure the stock price.
Wedbush analyst Yun Zhong holds a 0-star rating with a -7.0% average return and only a 40.1% success rate, raising concerns about the reliability of Buy ratings on Wave Life Sciences.
Abbott is completing its acquisition of Exact Sciences on March 23, which could strain capital resources and introduce integration risks during a period of already weak share performance.
Zacks Equity Research analysts highlight Abbott Laboratories (ABT) as one of five stocks featured in their latest daily research output, alongside Eli Lilly, RTX Corp, Ohio Valley Banc, and Rave Restaurant Group. The analysis notes that ABT shares have declined 15.1% over the past year, which is significantly less severe than the Zacks Medical Products industry's decline of 20.6%, suggesting relative resilience. Despite a diversified portfolio offering prospects through 2026, the company faces several headwinds including macroeconomic uncertainty, import tariffs, and ongoing pressures from its China operations.
The report identifies the Medical Devices segment as a primary growth engine, driven by the FreeStyle Libre continuous glucose monitor franchise and strategic expansion across diabetes care markets. Additionally, underlying demand in Diagnostics outside of the saturated COVID-19 space is improving, with momentum gaining in Core Laboratory and Point of Care sectors that are less reliant on the Chinese market. The company also maintains a constructive outlook for its biosimilar strategy, which supports continued growth in emerging markets within its EPD division.
However, the Nutrition business unit is currently in transition as it attempts to recover from recent near-term volume and pricing issues; management expects a return to growth in the second half of 2026. While Abbott’s strong product pipeline provides new prospects, the analysis concludes that current valuation suggests investors recognize improved earnings power but are cautious regarding long-term upside due to external risks like tariffs and limited visibility in specific geographic regions.
Zacks released daily reports on Eli Lilly, RTX, Abbott, Ohio Valley Banc, and Rave Restaurant Group on March 24, 2026.
Eli Lilly and RTX shares surged over 22% driven by drug demand, defense orders, and record backlogs.
Abbott declined while facing nutrition transition issues, but maintains a strong medical devices and diagnostics pipeline.
Ohio Valley Banc gained via lending optimization despite emerging credit quality pressures in commercial assets.
Rave Restaurant Group underperformed due to unit expansion limits and structural drag from its Pie Five brand.
- 📈 Zacks Equity Research analysts published new daily reports covering major stocks including Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc, and Rave Restaurant Group on March 24, 2026.
- 💊 Eli Lilly's shares have outperformed the large cap pharmaceuticals industry by 23.4% over six months driven by strong demand for GLP-1 drugs Mounjaro and Zepbound.
- 🚀 Lilly continues to expand its portfolio with new launches like Kisunla and Omvoh, plus an oral GLP-1 obesity pill called orforglipron expected this year.
- ⚠️ Investors face potential headwinds for Eli Lilly from declining Trulicity sales, pricing pressure on existing drugs, and emerging competition in the diabetes and obesity markets.
- 🛡️ RTX Corp. shares have outperformed the aerospace-defense industry by 22.8% due to strong defense orders from the Pentagon and allies alongside improving global commercial air traffic.
- 🔋 RTX reported a record backlog of $268 billion as of December 31, 2025, supported by steady volumes in large commercial engines and Pratt Canada operations.
- 🏭 The aerospace sector faces ongoing supply-chain challenges and risks related to recent U.S. government import tariffs that could adversely impact RTX's growth momentum.
- 🩺 Abbott Laboratories' shares have declined 15.1% over the past year, though the company maintains a strong product pipeline supporting growth into 2026.
- 🧬 Abbott's Medical Devices segment is driven by the FreeStyle Libre CGM franchise and expansion in Diabetes Care, while Diagnostics sees improving demand outside China.
- 🍽️ Abbott's Nutrition business is transitioning after near-term volume and pricing issues, with Adult Nutrition innovations expected to support growth starting in the second half of 2026.
- 🏦 Ohio Valley Banc shares have outperformed the Midwest banking industry by 15.6% due to balance-sheet optimization and a strategic shift toward higher-yielding commercial lending.
- ⚠️ The regional bank faces elevated credit sensitivity from its increased concentration in commercial assets, with early signs of asset quality pressure emerging.
- 🍕 Rave Restaurant Group shares have underperformed the restaurant industry by 28.9% due to limited net unit expansion and structural drag from its Pie Five brand.
- 💸 Rave's revenue visibility is constrained by reliance on incentive income, though the company offers a differentiated asset-light franchise model anchored by Pizza Inn's buffet strategy.
- 📉 The market currently prices limited growth potential for Rave Restaurant, leaving future upside dependent on sustained unit expansion and successful brand stabilization.
Bullish Signals
Abbott shares dropped only -15.1% vs industry -20.6% due to strong 2026 pipeline.
FreeStyle Libre CGM drives Medical Devices expansion and future growth.
Diagnostics gains momentum in emerging markets outside China.
Biosimilar strategy supports sustained EPD segment growth in emerging markets.
Nutrition business targets return to growth by mid-2026.
RTX shares rose +22.8% vs industry -2.6% on massive $268 billion backlog.
Eli Lilly outperformed with +23.4% gains driven by GLP-1 demand.
New drugs like Kisunla and Omvoh boost top-line growth.
Ohio Valley Banc gained +15.6% via margin expansion from lending shifts.
Efficiency gains at Ohio Valley Banc enhance scalability and stability.
Risk Factors
Abbott shares down -15.1% while Nutrition growth delayed until H2 2026.
Trulicity sales decline and pricing pressure hurt top-line growth.
Macro uncertainty, tariffs, and China risks limit Abbott visibility.
Eli Lilly faces GLP-1 competition threatening top-line drivers.
Supply chain issues and U.S. tariffs risk RTX Corp earnings.
Ohio Valley Banc faces credit concentration and fee income decline.
Rave shares down -28.9% due to weak unit expansion.
Pie Five unit contraction and weak sales drag Rave growth.
Rave revenue volatility stems from reliance on incentive income.
Bullish Signals
Abbott Laboratories shares have outperformed the broader industry decline of -20.6%, dropping only -15.1% over the past year due to a strong product pipeline supporting growth into 2026.
The company's Medical Devices segment, led by the FreeStyle Libre CGM franchise, remains a key driver for future expansion.
Diagnostics demand is improving outside of China as Core Laboratory and Point of Care gain momentum in emerging markets.
Abbott maintains a constructive outlook on its biosimilar strategy, which supports sustained growth in the EPD segment across emerging markets.
The Nutrition business is positioned to support a return to growth in the second half of 2026 following current near-term volume and pricing challenges.
RTX has outperformed the Aerospace-Defense industry with shares rising +22.8% versus -2.6%, fueled by ample orders for defense products from the Pentagon and foreign allies.
Strong volumes and a favorable mix across commercial engines are expected to sustain growth momentum, resulting in a massive backlog of $268 billion as of Dec. 31, 2025.
Eli Lilly has outperformed its industry with +23.4% gains over the past six months compared to +14%, driven by robust demand for GLP-1 drugs Mounjaro and Zepbound.
New drugs like Kisunla, Omvoh, and Jaypirca are actively contributing to top-line growth alongside rapid pipeline progress in obesity with oral GLP-1 orforglipron expected to launch this year.
Ohio Valley Banc has outperformed its industry with +15.6% gains over six months as balance-sheet optimization and a shift toward higher-yielding lending drive margin expansion.
Operating efficiency gains and disciplined expense management at Ohio Valley Banc enhance scalability, while a stable core deposit base underpins funding needs.
Risk Factors
Abbott Laboratories shares have declined -15.1% over the past year, significantly lagging its industry peer group.
The company faces near-term volume and pricing woes in its Nutrition segment as it transitions back to growth expected only by the second half of 2026.
Macro uncertainty, tariffs, and China pressures limit Abbott's near-term visibility despite its diversified portfolio.
Abbott is facing declining sales on Trulicity and rising pricing pressure on some drugs which acts as a headwind to top-line growth.
Potential competition in the GLP-1 diabetes/obesity market poses a threat to Eli Lilly's top-line drivers.
Supply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX Corp.
Uncertainties created by recent U.S. government-imposed import tariffs pose a specific risk for RTX Corp.
Ohio Valley Banc faces credit sensitivity risks as greater concentration in commercial assets elevates vulnerability to early signs of asset quality pressure.
Ohio Valley Banc is experiencing declining fee income and relies heavily on balance-sheet-driven earnings, highlighting evolving revenue risks.
Rave Restaurant Group's shares have underperformed the sector by -28.9% over the past six months due to limited net unit expansion and reliance on system-wide sales.
Pie Five remains a structural drag for Rave Restaurant with ongoing unit contraction and weak sales contributing to growth constraints.
Rave Restaurant's revenue visibility is impacted by its reliance on incentive income which creates volatility in earnings.
Abbott Laboratories (ABT) officially closed its $21 billion acquisition of Exact Sciences (EXAS) on March 23, 2026, completing a merger that saw all shares of the target company exchanged for $105.00 cash per share. The transaction was executed through a merger with Badger Merger Sub I, Inc., an entity fully controlled by Abbott, utilizing both existing cash reserves and borrowed funds. Precursor trading on the public market ceased after March 20, 2026, as Nasdaq suspended trading before the opening bell on March 23, following a formal request to delist from the exchange. Dissenting stockholders and certain excluded categories were exempted from the cash conversion, and the final aggregate value of the deal may see minor adjustments based on the conversion of outstanding convertible debt instruments at predetermined rates.
Following the merger completion, Exact Sciences' entire board and executive team stepped down, with all directors tendering their resignations and corporate officers exiting their roles. Equity compensation plans, including stock options, restricted stock units, and deferred stock units, were addressed by converting awards into cash payment rights or transferring them to Abbott with adjusted provisions. The deal received approval from stockholders, with 67.56% of votes cast supporting the agreement, after necessary regulatory clearances were secured prior to closing. Prior to the acquisition, Exact Sciences had a market capitalization near $20 billion but recorded a net loss of $1.10 per share over the trailing twelve-month period against revenues of $3.25 billion, while Wall Street had forecasted earnings of $1.27 per share for the upcoming fiscal year.
The acquisition significantly strengthens Abbott's position as a frontrunner in oncology screening and diagnostic testing, positioning it to serve millions more patients worldwide. The combined entity now owns Exact Sciences as a subsidiary, leveraging recent federal legislation that established a Medicare reimbursement framework for multi-cancer early detection tests—a development Exact Sciences had identified as critical for advancing cancer detection capabilities before the deal was finalized. Abbott plans to file documentation to terminate its Securities and Exchange Commission reporting requirements once the delisting process is fully completed.
🏛️ Abbott acquired Exact Sciences for $21 billion on March 23, 2026.
💰 All EXAS shares converted to cash at $105 per share.
⚠️ Exact Sciences' entire leadership team resigned following the merger.
🏛️ Abbott (ABT) successfully closed its $21 billion acquisition of Exact Sciences (EXAS) on March 23, 2026.
💰 All outstanding shares of Exact Sciences were converted to cash at a price of $105.00 per share, subject to certain exclusions.
📉 Nasdaq suspended trading in EXAS shares prior to market open on the closing date, with final public trading occurring on March 20, 2026.
⛔ The entire board and executive management team of Exact Sciences resigned following the completion of the merger.
🚀 Share prices for Exact Sciences surged approximately 130% over the twelve months leading up to the acquisition offer.
📊 Exact Sciences had a market capitalization near $20 billion with recent annual revenues of $3.25 billion against a net loss.
💼 The deal was executed through a merger with Badger Merger Sub I, Inc., an entity controlled by Abbott Laboratories.
🏦 Approximately $21 billion in transaction value was funded using Abbott's existing cash reserves combined with borrowed funds.
✅ Regulatory clearances from all necessary authorities were obtained prior to the official closing date of March 23, 2026.
👥 Stockholders voted to approve the merger, with 67.56% of votes cast in support of the transaction agreement.
🔄 Convertible debt securities issued by Exact Sciences are now set to convert exclusively into cash payments based on the acquisition price.
👉 Incentive plan equity awards, including stock options and RSUs, were either converted to cash or transferred to Abbott with adjustments.
📝 Corporate governing documents were amended as part of the transaction closure process.
🏥 Abbott states the acquisition solidifies its position as a leader in oncology screening and diagnostic testing services.
⚖️ Recent federal legislation establishing Medicare reimbursement for multi-cancer early detection tests was identified as a key benefit.
Bullish Signals
Abbott officially closed its $21 billion acquisition of Exact Sciences on March 23, 2026, solidifying its position as a frontrunner in oncology screening and diagnostic testing.
Exact Sciences shares surged approximately 130% in the twelve months preceding Abbott's offer, demonstrating strong investor confidence leading up to the deal.
The transaction was executed via a merger with Badger Merger Sub I, Inc., fully controlled by Abbott, with stockholders receiving $105.00 cash per share for a total value supported by existing cash reserves and borrowed funds.
Recent federal legislation has created a Medicare reimbursement framework for multi-cancer early detection screening tests, providing a critical regulatory advancement that Exact Sciences had identified as essential for advancing cancer detection capabilities.
67.56% of votes cast previously supported the transaction agreement, indicating strong stockholder alignment with the strategic move to serve millions more patients worldwide.
Risk Factors
Abbott is financing a $21 billion acquisition partly through borrowed funds, increasing leverage and financial risk.
Exact Sciences posted a net loss of $1.10 per share against $3.25 billion in revenue over the trailing twelve months, indicating significant operational unprofitability prior to the merger.
Wall Street analysts forecasted earnings of $1.27 per share for the upcoming fiscal year, suggesting management may have been unable to meet these positive market expectations with recent performance data showing a loss.
The entire board and executive team of Exact Sciences stepped down following the merger, raising concerns about potential instability or a lack of leadership continuity during the integration process.
Approximately 32% of stockholders voted against the merger agreement (as only 67.56% supported it), indicating significant dissent within the investor base.
Dissenting stockholders and certain excluded categories were exempted from the standard $105.00 per share cash conversion, creating an uneven exit value for a portion of shareholders.
Nasdaq trading was suspended on March 23, 2026, with final public market trading ending on March 20, limiting liquidity and potentially trapping investors before the deal closed.
Abbott Laboratories (NYSE: ABT) continues to be highlighted as an attractive investment following positive clinical trial results for its FreeStyle Libre continuous glucose monitoring technology. On March 13, Benchmark reiterated a Buy rating for the company with a price target of $145 per share, citing strong data from a UK-based FreeDM trial involving patients with Type 2 diabetes on basal insulin therapy. The study found that individuals using FreeStyle Libre achieved superior glucose results compared to those utilizing traditional whole blood glucose meters with fingerstick samples. These findings were further corroborated by a separate interventional trial conducted in Italy, both of which underscore the growing demand for expanded insurance coverage for continuous glucose monitoring technology across European nations where it currently lacks official reimbursement.
The article also notes that while no immediate decision is expected from U.S. regulators, the Centers for Medicare & Medicaid Services (CMS) is considering expanding compensation structures for such devices in the United States. Benchmark views Abbott Laboratories as well-positioned to capitalize on this potential policy shift, given its status as a leading global healthcare company and top provider of continuous glucose monitoring systems. Abbott's business portfolio spans branded generic medications, medical devices, diagnostics, and nutritional products, positioning it for diverse growth opportunities within the healthcare sector.
However, the text includes a speculative promotional element suggesting that alternative AI stocks may offer greater upside potential than ABT in a shorter timeframe, implying a 10,000% upside opportunity in an unspecified AI stock report. The content concludes by providing various unrelated investment links and performance metrics for Insider Monkey's subscription service, noting returns since its inception in May 2014 through February 18th, 2026, while stating that the financial advice content is not affiliated with specific stock recommendations beyond the reiterated Buy rating for Abbott.
📈 Analysts maintain a Buy rating for Abbott Laboratories with a $145 price target.
💉 Continuous glucose monitoring showed superior outcomes for Type 2 diabetes patients in trials.
🏥 US CMS and European insurers face pressure to expand coverage for this technology.
📈 Benchmark reiterated a Buy rating for Abbott Laboratories (NYSE: ABT) and set a $145 price target following the FreeDM trial results.
💉 The FreeDM trial showed that Type 2 diabetes patients using continuous glucose monitoring technology achieved better glucose outcomes than those using fingerstick blood samples.
🇪🇺 Positive UK trial findings were supported by a second interventional trial conducted in Italy at the same conference.
⚠️ Results highlight a need for expanded insurance coverage of continuous glucose monitoring in European nations where it is not officially covered.
🇺🇸 CMS is considering expanding compensation for continuous glucose monitoring in the US, positioning Abbott to benefit from potential policy changes.
🏥 Abbott Laboratories is a global healthcare company manufacturing branded generic medications, medical devices, diagnostics, and nutritional items.
⚖️ Benchmark notes investment risks but maintains conviction that AI stocks may offer higher returns over shorter time frames compared to ABT.
🔗 The article concludes with links to related content regarding other stock picks and healthcare equipment recommendations from analysts.
Risk Factors
Better AI stocks offer higher returns faster than Abbott.
Alternative AI stock cited with 10,000% upside potential.
European CGM coverage pending limits immediate Abbott profitability.
CMS compensation expansion uncertainty hinders near-term US revenue growth.
Bullish Signals
Benchmark reiterated a Buy rating for Abbott Laboratories (NYSE: ABT) with a price target of $145 following encouraging results from the FreeDM trial.
The trial demonstrated that patients with Type 2 diabetes on basal insulin therapy achieved better glucose results using FreeStyle Libre continuous glucose monitoring technology compared to fingerstick blood samples.
A second interventional trial from Italy supported the UK findings, further validating Abbott's FreeStyle Libre technology and highlighting expansion opportunities in European nations.
Abbott is well-positioned to profit from potential CMS decisions to expand compensation for continuous glucose monitoring in the US.
Risk Factors
While Abbott receives a Buy rating for diabetes trial results, the article explicitly warns that some AI stocks hold greater promise for delivering higher returns in a shorter time frame.
The article suggests investors seeking significant upside potential should consider other 'AI stock' opportunities over ABT, noting a specific claim of 10,000% upside potential for an alternative stock instead.
Expansion of insurance coverage for continuous glucose monitoring in European nations is still pending and not officially covered in some regions, limiting Abbott's immediate profitability from this segment.
No decision on expanding CMS compensation in the US is expected 'very soon,' creating uncertainty around near-term revenue growth from this development.
Abbott Laboratories has finalized its acquisition of Exact Sciences, a move that significantly expands its capabilities in cancer screening and precision oncology diagnostics. The transaction was completed on March 23, 2026, with Abbott paying $105 per share in cash to make Exact a wholly owned subsidiary, a process that ended Exact's trading on Nasdaq on March 20, 2026. By integrating Exact Sciences' flagship tests, including Cologuard, Oncotype DX, Oncodetect, and Cancerguard, Abbott positions itself as a leader in the approximately $60 billion U.S. cancer screening and precision oncology segments. This acquisition establishes a new growth vertical focused on preventative, predictive, and personalized diagnostics within Abbott's broader portfolio, which also includes medical devices, nutritionals, and branded generics.
Analysts have issued a Buy rating on Abbott stock with a price target of $158.00, citing solid underlying financial performance and strong free cash flow as key positives. However, TipRanks' AI Analyst provided a Neutral score for the stock, noting that these strengths are offset by weak technical momentum and a relatively expensive valuation. Investors are also aware of additional uncertainties surrounding the company's balance sheet, specifically due to incomplete 2025 data and the substantial debt financing associated with the acquisition. This strategic move is expected to strengthen Abbott's market positioning in the fast-growing field of cancer diagnostics, serving patients across more than 160 countries with a global workforce of about 122,000 people.
🤝 Abbott finalized Exact Sciences acquisition for $105/share on March 23, 2026.
🧬 Deal adds Cologuard and Oncotype DX to expand cancer screening leadership.
💰 Analysts view fundamentals positively despite concerns over valuation and debt risks.
🏥 Abbott Laboratories has finalized its acquisition of Exact Sciences, integrating it as a wholly owned subsidiary.
💰 The deal was completed on March 23, 2026, for a purchase price of $105 per share in cash.
📉 Trading on the Nasdaq ended for Exact Sciences prior to the closing on March 20, 2026.
🧬 Abbott now owns flagship tests including Cologuard, Oncotype DX, Oncodetect, and Cancerguard.
🚀 The acquisition positions Abbott as a leader in the roughly $60 billion U.S. cancer screening and precision oncology segments.
🔍 This expands Abbott's portfolio with a focus on early cancer detection and personalized treatment diagnostics.
📈 Analysts maintain a Buy rating with a price target of $158.00 for Abbott stock.
🤖 Spark AI Analyst currently rates ABT as Neutral due to mixed signals.
💵 Strong free cash flow and earnings guidance support the positive analyst view on Abbott's fundamentals.
⚠️ Concerns persist regarding weak technical momentum and an expensive valuation relative to peers.
🏦 The company faces uncertainty from incomplete 2025 balance sheet data and significant debt financing needs.
🌍 Abbott employs approximately 122,000 people and serves patients in over 160 countries globally.
Risk Factors
Financed by large debt introducing significant leverage and repayment risks.
Incomplete 2025 data limits full visibility into financial health.
Analysts rate stock Neutral due to weak technical momentum concerns.
Expensive valuation leaves little margin for error if growth falters.
Bullish Signals
Abbott Laboratories finalized its acquisition of Exact Sciences on March 23, 2026, for $105 per share, creating a new growth vertical in cancer diagnostics.
The deal positions Abbott as a leader in the approximately $60 billion U.S. cancer screening and precision oncology segments by adding key products like Cologuard, Oncotype DX, Oncodetect, and Cancerguard.
Analysts maintain a Buy rating with a $158.00 price target, indicating bullish sentiment despite recent market volatility.
The acquisition strengthens Abbott's portfolio for early cancer detection and personalized treatment decisions in the fast-growing preventative, predictive, and personalized diagnostics market.
Recent performance highlights include solid underlying financial metrics, particularly strong free cash flow generation, supporting the company's valuation and expansion plans.
Risk Factors
The acquisition of Exact Sciences is financed with a large amount of debt, introducing significant financial leverage and repayment risks to Abbott Laboratories.
Uncertainty remains regarding the incomplete 2025 balance sheet data, which limits full visibility into Abbott's financial health before the deal closes.
Analyst sentiment is conflicted, with Spark AI rating ABT as Neutral due to concerns over weak technical momentum despite positive fundamentals.
The stock trades at a relatively expensive valuation compared to its historical norms, leaving little margin for error if growth expectations are not met.
Abbott Laboratories (NYSE: ABT) announced on March 23, 2026, that it has completed its acquisition of Exact Sciences. Following the completion of the deal, Exact Sciences became a wholly owned subsidiary of Abbott, and trading for Exact Sciences shares ceased on Nasdaq with March 20, 2026, being the final trading day. Robert B. Ford, Abbott's CEO, stated that the company's global scale and operational excellence will expand access to early cancer detection tools and personalized treatments, leveraging Exact Sciences' deep expertise.
The transaction positions Abbott as a leader in fast-growing cancer screening and diagnostics segments, specifically within the $60 billion U.S. cancer screening and precision oncology diagnostics market. Abbott now offers a comprehensive suite of products for early cancer detection and treatment support, including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard®. Additionally, Abbott has acquired a pipeline of next-generation cancer screening technologies designed to detect cancer earlier, optimize treatment decisions, and enable regular monitoring for disease management.
The acquisition is expected to serve millions of additional people and establish leadership in one of healthcare's fastest-growing areas as global cancer incidence rises. This adds a new growth vertical to Abbott, which already has high-single-digit growth expectations. The press release concludes with standard forward-looking statements regarding integration risks, synergy realization, and uncertainties related to future operations and financial performance.
Note: While the provided text contains some unrelated boilerplate content in German regarding energy markets and a different ticker (ABB/BL), the core news story focuses entirely on Abbott's completion of the Exact Sciences acquisition, making this article valuable for investors seeking information on this major transaction.
✅ Abbott completed acquiring Exact Sciences to lead the $60B cancer screening market.
🏥 New offerings like Cologuard® and Oncotype DX® enable comprehensive early detection.
👨⚕ Global scale expansion aims to increase access to preventative diagnostic tools.
🏥 Abbott has officially completed its acquisition of Exact Sciences to become a leader in cancer screening and diagnostics.
📅 The transaction closed on March 20, 2026, with that date marking the last day of trading for Exact Sciences shares on Nasdaq.
📑 Upon completion, Exact Sciences became a wholly owned subsidiary of Abbott under the terms of their merger agreement.
💼 This deal establishes leadership in the fast-growing U.S. cancer screening and precision oncology diagnostics segments valued at $60 billion.
🚀 The acquisition adds new growth to Abbott's portfolio, reinforcing its high-single-digit growth expectations for the business unit.
🧬 Abbott now offers a comprehensive suite including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard® for early detection.
👨⚕️ Robert B. Ford, Abbott's CEO, stated that the company's global scale will expand access to tools for early cancer detection.
🌍 The deal supports Abbott's mission to advance preventative, predictive, and personalized diagnostics as global cancer incidence rises.
🧪 Next-generation products have been added to the pipeline to detect cancer earlier and optimize treatment decisions.
⚠️ Abbott disclosed forward-looking statements regarding risks related to integration operations and realizing anticipated synergies.
📄 Interested parties can review detailed risk factors in Abbott's and Exact Sciences' 10-K filings from December 31, 2025.
🌐 Abbott continues its broader mission with 122,000 colleagues serving people in over 160 countries across various healthcare segments.
Substantial integration risks threaten failure to combine operations.
Anticipated synergies may be unrealized or delayed significantly.
Uncertainty exists in post-transaction business plan implementation.
Forward-looking statements carry no obligation for revision updates.
Bullish Signals
Abbott has completed the acquisition of Exact Sciences, establishing itself as a leader in the fast-growing cancer screening and diagnostics segments.
The transaction adds a new growth vertical to Abbott's portfolio, expanding its presence in the approximately $60 billion U.S. cancer screening and precision oncology diagnostics market.
Abbott now offers a comprehensive suite of products including the Cologuard® test, Oncotype DX®, Oncodetect®, and Cancerguard®, enhancing early detection capabilities.
Robert B. Ford, CEO, stated that Abbott's global scale and operational excellence will expand access to tools for early cancer detection and personalized treatments.
The acquisition enables Abbott to serve millions of additional people, reinforcing its mission to make healthcare more accessible.
Abbott now possesses a leading pipeline of next-generation screening technologies designed to detect cancer earlier and enable regular monitoring to help patients manage the disease.
Risk Factors
The acquisition introduces substantial integration risks, including the potential for Abbott to fail in successfully integrating Exact Sciences' operations.
There is a significant risk that anticipated synergies and benefits from the transaction may not be realized or will take longer than expected to materialize.
Abbott must successfully implement its plans and forecasts regarding Exact Sciences' business post-transaction, which carries uncertainty.
Readers are cautioned against relying on forward-looking statements regarding the acquisition's success, as Abbott undertakes no obligation to release revisions to these statements.
Citi upgraded Intuitive Surgical (ISRG) to a Buy rating from Neutral while maintaining its Buy ratings on Stryker (SYK) and Abbott Laboratories (ABT), citing healthy fundamentals for the medical technology sector despite recent market volatility. The firm, led by analyst Joanne Wuensch, argues that Intuitive Surgical's sell-off has been driven by broader macro fear rather than any deterioration in the business, particularly noting the double-digit growth trajectory continues with the da Vinci 5 platform in its early adoption cycle. Specifically, Citi cut the price target on Abbott by $4 to reflect the more modest growth profile of a diversified healthcare giant following Q4 reports, while adding a 90-day catalyst watch to Stryker to monitor data from its Mako RPS handheld robotic system set for limited release in 2026.
Intuitive Surgical is the primary focus of the upgrade, with Citi highlighting that the company delivered one of its strongest years recently despite trading sharply off its highs. In Q4 2025, ISRG posted revenue of $2.87 billion, an 18.76% year-over-year increase, and non-GAAP EPS of $2.53 against a consensus of $2.26. The da Vinci 5 system saw significant momentum with 303 units placed in Q4 alone, bringing the total installed base to 11,106 systems, up 12%. Citi maintains a price target of $590 for ISRG, implying upside from its current trading level of approximately $485.85, even though the stock trades at a premium forward P/E of roughly 49x reflecting its competitive moat in robotic surgery.
Stryker is noted for crossing the $25 billion annual revenue mark in 2025 with full-year revenue of $25.12 billion, up 11.16%, and adjusted operating margins expanding at least 100 basis points for the second consecutive year. Currently trading around $358.65, Stryker's Citi price target is $420, with a forward P/E of roughly 24x that reflects its mature and diversified business mix compared to Intuitive. Abbott Laboratories is highlighted for its pending $21 billion acquisition of Exact Sciences expected to close in Q2 2026, which adds cancer diagnostics to its portfolio, while its medical devices segment continues to grow with CGM sales up 15% to $2.0 billion despite overall revenue growth moderating to 4.42% in Q4.
The broader market context shows the VIX surged to 25.50 as of early March, sitting at the 92.6th percentile of its 12-month range, indicating significant fear that has compressed valuations indiscriminately across the sector. Citi believes this macro backdrop is responsible for the price action rather than a lack of operational momentum, particularly for Intuitive Surgical which was trading down 14.2% year-to-date after closing near a 52-week high in late 2025. The consensus analyst price target for Intuitive is even higher at $609.82, suggesting that the current market price may not fully reflect the long-term potential of the company's robotic-assisted surgery growth and earnings leverage capabilities.
📈 Citi upgraded Intuitive Surgical and opened a catalyst watch on Stryker.
🔭 da Vinci robotic platform adoption surged with 303 systems placed in Q4.
💊 Abbott maintained a Buy rating despite a price target cut for modest growth.
⚠ High market fear has compressed MedTech valuations despite healthy underlying fundamentals.
📈 Citi upgraded Intuitive Surgical (ISRG) from Neutral to Buy while opening a 90-day catalyst watch on Stryker (SYK).
📉 Analyst Joanne Wuensch maintained a Buy rating for Abbott (ABT) but trimmed its price target by $4 following Q4 earnings.
💊 The firm argues that U.S. medical technology fundamentals remain healthy and intact despite recent broad market volatility and sector pullbacks.
🤖 Intuitive Surgical delivered strong Q4 2025 results with revenue of $2.87 billion (up 18.76%) and non-GAAP EPS of $2.53 versus the $2.26 estimate.
🔭 The da Vinci 5 robotic platform continues its multi-year adoption cycle, placing 303 systems in Q4 alone to reach a total installed base of 11,106.
🦾 Stryker crossed a significant milestone by surpassing $25 billion in annual revenue for the first time, reaching full-year revenue of $25.12 billion up 11.16%.
⚠️ Citi added a catalyst watch to Stryker due to potential near-term inflection points from early data on the Mako RPS handheld robotic system.
🏥 Abbott reported modest Q4 revenue growth of 4.42% with its medical devices segment providing clear signals, including $2.0 billion in CGM sales up 15%.
🤝 The price target cut for Abbott reflects the more modest growth profile of a diversified healthcare giant rather than any structural concerns about the company.
💰 Stryker's adjusted operating margins expanded at least 100 basis points for the second consecutive year, strengthening its financial foundation.
🔮 Intuitive Surgical's Q4 placement of 303 da Vinci systems was more than double the 174 units placed in the same quarter a year prior.
📉 Abbott's shares are down 18% over the past year while facing significant pressure from its pending $21 billion acquisition of Exact Sciences.
⚖️ Intuitive Surgical trades at a premium valuation of roughly 49x forward earnings, reflecting its strong competitive moat in robotic-assisted surgery.
🛡️ Citi suggests that Intuitive has been unduly caught in the market downdraft without any deterioration in the underlying business fundamentals.
🌐 The broader stock market fear, indicated by the VIX surging to 25.50, has compressed valuations indiscriminately across the MedTech sector.
Bullish Signals
Intuitive Surgical upgraded to Buy by Citi.
Intuitive Q4 2025 revenue hit $2.87B up 18.76%.
da Vinci 5 systems placed surged to 303 in Q4.
Stryker revenue surpassed $25B for the first time.
Stryker operating margins expanded for second consecutive year.
Abbott CGM sales grew 15% to reach $2.0B in Q4.
Abbott acquiring Exact Sciences for $21B pending close.
Intuitive trades at 49x forward earnings with da Vinci growth guidance.
Stryker trades at 24x P/E near $424.89 analyst target.
Abbott offers 54-year dividend growth streak at 20x P/E.
Risk Factors
Abbott shares down 18%; revenue grew only 4.42% YoY.
Citi cut Abbott target $4 reflecting modest growth profile.
Intuitive Surgical faces 1.2% tariff headwind on top-line.
da Vinci procedure growth expected to slow to 13%-15% in 2026.
Bullish Signals
Intuitive Surgical was upgraded to a Buy rating by Citi, signaling strong investor confidence despite recent market volatility.
Intuitive delivered exceptional performance in Q4 2025 with revenue of $2.87 billion up 18.76% year-over-year and non-GAAP EPS of $2.53 versus a consensus estimate of $2.26.
The da Vinci 5 platform adoption is accelerating, placing 303 systems in Q4 alone compared to 174 a year earlier, with the total installed base growing 12% to reach 11,106 systems.
Stryker crossed a significant milestone by surpassing $25 billion in annual revenue for the first time, achieving full-year revenue of $25.12 billion up 11.16%.
Stryker has demonstrated consistent double-digit revenue and earnings growth as the foundation for its Buy rating, with adjusted operating margins expanding at least 100 basis points for the second consecutive year.
Abbott's medical devices segment provided a clear growth signal with CGM sales up 15% to reach $2.0 billion in Q4.
Abbott is positioned for long-term transformation via its pending $21 billion acquisition of Exact Sciences, expected to close in Q2 2026, which adds a cancer diagnostics dimension.
Intuitive Surgical trades at roughly 49x forward earnings with management guidance calling for da Vinci procedure growth of 13% to 15% in 2026.
Stryker offers meaningful upside to analyst targets with a forward P/E of roughly 24x and the broader analyst consensus price target sitting at $424.89.
Abbott maintains a solid valuation case for income-oriented investors with a forward P/E near 20x and an impressive 54-year dividend growth streak.
Risk Factors
The stock is trading around $485.85, down 14.2% year-to-date after closing 2025 near a 52-week high of $603.88, indicating significant price suppression despite strong fundamentals.
Citi trimmed its price target on Abbott by $4 to reflect the more modest growth profile typical of a diversified healthcare giant rather than addressing any immediate structural risks.
Abbott shares are down 18% over the past year and posted only a modest 4.42% year-over-year revenue gain in Q4, trailing peers in growth performance.
The VIX has surged to 25.50, sitting at the 92.6th percentile of its 12-month range, suggesting broad-market fear is compressing valuations indiscriminately and dragging down strong names like Intuitive Surgical without fundamental justification.
Intuitive Surgical faces a tariff headwind of approximately 1.2% of revenue already baked into management's outlook for the next year, which could suppress top-line growth.
The company's 2026 guidance anticipates da Vinci procedure growth deceleration to 13%-15%, down from double-digit speeds in previous years, signaling a potential slowdown in adoption momentum.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
